| ￥2520 | |
| Z03802 | |
|
|
|
|
|
|
|
|
|
| Species | Bovine | |
| Protein Construction |
|
|
| Purity | ≥ 95% as analyzed by SDS-PAGE | |
| Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | |
| Biological Activity | ED50 < 0.2 ng/ml, measured by a cell differentiation assay using TF-I cells, corresponding to a specific activity of > 5.0×106 units/mg. | |
| Expression System | E.coli | |
| Theoretical Molecular Weight | 19.9 kDa | |
| Apparent Molecular Weight | ~ 20.2 kDa, on SDS-PAGE under reducing conditions. | |
| Formulation | Lyophilized from a 0.2 μm filtered solution in 1×PBS, pH 7.4 | |
| Reconstitution | Before opening, centrifuge the vial briefly to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O up to 100 μg/ml | |
| Storage & Stability | Upon receiving, this product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles. |
»
»
Lane 1: 2 µg of LIF,Bovine under reducing condition (R)
Lane 2: 2 µg of LIF,Bovine under non-reducing condition (NR) (N)
The purity is greater than 95% as analyzed by SDS-PAGE
»
ED50 < 0.2 ng/ml, measured by a cell differentiation assay using TF-I cells, corresponding to a specific activity of > 5.0×106 units/mg. »
| Target Background | LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes (By similarity). |
| Synonyms | LIF |
For research use only. Not intended for human and animal therapeutic or diagnostic use.
